Boston, MA 03\/18\/2014 (wallstreetpr) –\u00a0The U.S. Food and Drug Administration (FDA) had granted three-year exclusivity for Amarin Corporation plc (ADR) (NASDAQ:AMRN)<\/b>\u2019s Vascepa and the exclusivity extends through July 25, 2015. The product is intended to treat cardiac patients with high triglycerides level.<\/p>\n
Vascepa<\/b><\/p>\n
Vascepa is one of Omega 3 fatty acids launched in January 2013. The product reduces the high triglycerides level in adult patients without raising bad cholesterol (LDL-C). It showed positive results when used alone as well as joint therapy in patients with Statin therapy.\u00a0 The product is approved by the FDA for multiple indications.<\/p>\n
Therapeutics Market<\/b><\/p>\n
Cardiovascular market is highly competitive with increasing patients\u2019 needs. Large number of products are available in the market to fight against triglycerides; however, the market is largely driven by Statin therapy.\u00a0 Traditionally, Statin molecules lowers the triglycerides level in cardiac patients; however, it has severe side effects such as raising the bad cholesterol in the blood stream. This compelled companies\u2019 to focus on alternatives like Omega 3 fatty acids.<\/p>\n
Competition<\/b><\/p>\n
In Omega 3 fatty acids market, generic products affect Amarin Corporation plc (ADR) (NASDAQ:AMRN)\u2019s market. Therefore, Amarin is seeking for the approval of five-year marketing exclusivity for Vascepa to fight against generic competition. As the cardiac disorder continue to grow globally with increasing lipid abnormalities including high levels of triglycerides and cholesterol in the blood stream. Vascepa is well accepted in the market as there are no side effects.<\/p>\n
Prospects<\/b><\/p>\n
In last 12 months, Amarin Corporation plc (ADR) (NASDAQ:AMRN)\u2019s Vascepa has received 40 issued and allowed U.S. patents to protect the exclusivity of Vascepa till 2030. With increasing advantage over other drugs, the FDA has granted three-year exclusivity for Vascepa. By performance, Vascepa is also reported increase in prescription and reported sales of $26.4 million in FY2013. Company anticipates opportunities in the cardiovascular therapies market and market exclusivity will support Vacepa\u2019s growth going forward.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/18\/2014 (wallstreetpr) –\u00a0The U.S. Food and Drug Administration (FDA) had granted three-year exclusivity for Amarin Corporation plc (ADR) (NASDAQ:AMRN)\u2019s Vascepa and the exclusivity […]<\/p>\n","protected":false},"author":9,"featured_media":17555,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3312,3313],"stock_ticker":[],"class_list":["post-17554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amarin-corporation-plc-adr-nasdaqamrn","tag-nasdaqamrn","entry"],"acf":[],"yoast_head":"\n